Navigation Links
Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
Date:9/24/2009

roduct," added Dr. Robinson.

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Whereas the Thai trial was conducted with a vaccine targeted for infections endemic to Thailand; the GeoVax vaccine is targeted for the "clade B" type of HIV-1 prevalent in the Americas, Europe and Australia.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicate
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
2. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
5. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
6. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
11. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... interface is the device," Nobel laureate Herbert Kroemer ... be found at the junctures where layers of ... nanotechnology, the interfaces between layers of metal oxides ... high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics and ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , a biotechnology company focused on the development and ... has entered into an in-vitro diagnostics patent license agreement ... , ,Under the agreement, which will be effective July ... in its products. Prodesse also receives the authority to ...
... monthly column, "Buzz Networks," will provide insights, descriptions, analysis, ... and concepts that are gaining credibility and providing utility ... deeply into the underlying technology, but rather will focus ... platforms. We look forward to your feedback and participation ...
... Wis. - It's not often that a tax is ... consumers start popping champagne corks over the recent elimination of ... know that getting some of their money back will require ... United States Treasury ruling has effectively eliminated the ...
Cached Biology Technology:Social computing in the Web 2.0 era 2Social computing in the Web 2.0 era 3Social computing in the Web 2.0 era 4Social computing in the Web 2.0 era 5Elimination of phone tax tempered by paperwork 2Elimination of phone tax tempered by paperwork 3
(Date:4/23/2014)... technique used to read quickly. It involves visual ... words and/ or sentences. Similarly to humans, biological ... "read" genetic information. Genes that need to be ... the encoding message, the easier it will be ... Gulbenkian de Cincia (IGC, Portugal) and Centre for ...
(Date:4/22/2014)... -- There are all sorts of signaling strategies in ... colorful tails; satin bowbirds build specialized stick structures, called ... and European bitterling males show off bright nuptial coloration ... method to communicate with others. , ... have profound fitness implications for individuals that are either ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... such, they are relatively well studied, especially in the ... most thoroughly. First eastern US butterfly species were described ... himself, over 250 years ago. For the last ... species diversity of eastern butterflies, and every nook and ...
... A*STAR,s Institute of Molecular and Cell Biology (IMCB) have ... the pathway leading to memory and learning impairment. The ... and could be used to explain defects in the ... established knowledge could potentially facilitate exploration of strategies to ...
... plant that,s been known to drive people daffy. It,s one ... a hard-to-control weed in ponds and small lakes. But it,s ... source to produce pharmaceuticals. Now, the genome of Greater Duckweed ... as a biofuel source a big boost. In a paper ...
Cached Biology News:Two new butterfly species discovered in eastern USA 2A*STAR scientists discover protein's role in human memory and learning functions 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: